Skip to content
Agriculture is essential to the U.S. economy – and to put food on the table for American families. And more than ever, it’s critical […]
Plant Biostimulant Act would offer clear market path for important ag biotech Read More »
Biotechnology Innovation Organization (BIO) members Bristol Myers’, Pfizer’s, and AbbVie’s drugs “are likely to be among 10 big-selling medicines subject to U.S. price negotiations
U.S. drug price negotiation already affecting Bristol Myers, Pfizer, AbbVie Read More »
While it deliberates on whether to support the expansion of the international waiver of IP protections for COVID-19 therapeutics and diagnostics, the United States
Last chance for public hearing on the COVID IP waiver expansion Read More »
The 2024 budget proposal President Biden officially released yesterday is facing rocky ground ahead calling for, among other things, more innovation-killing drug price controls
Drug price controls in Biden’s proposed budget hurtful for patients, R&D Read More »
The third anniversary of the COVID-19 pandemic on March 11 may feel to some like a relief as we transition into a post-COVID era.
As the COVID pandemic turns 3, are we ready for the next one? Read More »
On March 8, 2023, during the first markup of health care bills this year, the Health Subcommittee of the House Energy and Commerce Committee
Legislation potentially banning QALYs due to discrimination is under review Read More »
The 11th International IP Index was published by the U.S. Chamber of Commerce, highlighting the danger of COVID-19 IP infringement and its potential impact
U.S. Chamber’s IP Index highlights progress and new threats Read More »
To assure the broad adoption of cutting-edge preventative measures that can shield Americans in the future, vaccine policy has to be changed, according to
Why vaccine policy must keep up with the science Read More »
Health and Human Services (HHS) is set to assess three drug payment models for Medicare and Medicaid in response to President Biden’s proposal to
HHS releases new drug payment models—here’s what you need to know Read More »
On Thursday, the Centers for Medicare & Medicaid Services (CMS) released its proposed timeline for penalizing drug makers whose prices rise faster than inflation.
CMS releases timeline for inflation rebate on drug price increases Read More »
